CN112442456A - 葡萄球菌属菌株及其用途 - Google Patents
葡萄球菌属菌株及其用途 Download PDFInfo
- Publication number
- CN112442456A CN112442456A CN202010487042.8A CN202010487042A CN112442456A CN 112442456 A CN112442456 A CN 112442456A CN 202010487042 A CN202010487042 A CN 202010487042A CN 112442456 A CN112442456 A CN 112442456A
- Authority
- CN
- China
- Prior art keywords
- hair
- skin
- strain
- solution
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000191940 Staphylococcus Species 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 241000191963 Staphylococcus epidermidis Species 0.000 claims abstract description 18
- 201000004384 Alopecia Diseases 0.000 claims abstract description 16
- 230000003779 hair growth Effects 0.000 claims abstract description 14
- 231100000360 alopecia Toxicity 0.000 claims abstract description 10
- 210000004209 hair Anatomy 0.000 claims description 74
- 239000000284 extract Substances 0.000 claims description 34
- 239000002537 cosmetic Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 11
- 230000001737 promoting effect Effects 0.000 claims description 11
- 201000004624 Dermatitis Diseases 0.000 claims description 9
- 230000003658 preventing hair loss Effects 0.000 claims description 9
- 208000017520 skin disease Diseases 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 230000008591 skin barrier function Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000009759 skin aging Effects 0.000 claims description 7
- 208000003251 Pruritus Diseases 0.000 claims description 6
- 206010072170 Skin wound Diseases 0.000 claims description 6
- 239000000686 essence Substances 0.000 claims description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 206010015150 Erythema Diseases 0.000 claims description 5
- 208000010201 Exanthema Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000024780 Urticaria Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 231100000321 erythema Toxicity 0.000 claims description 5
- 201000005884 exanthem Diseases 0.000 claims description 5
- 206010037844 rash Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 230000036560 skin regeneration Effects 0.000 claims description 4
- 235000015961 tonic Nutrition 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 229960000716 tonics Drugs 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 230000003716 rejuvenation Effects 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000003712 decolorant Substances 0.000 claims description 2
- 239000002274 desiccant Substances 0.000 claims description 2
- 239000000834 fixative Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000118 hair dye Substances 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 231100000046 skin rash Toxicity 0.000 claims 2
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 206010014190 Eczema asteatotic Diseases 0.000 claims 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 50
- 210000003491 skin Anatomy 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 26
- 230000000694 effects Effects 0.000 description 14
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 208000024963 hair loss Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003676 hair loss Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000004927 skin cell Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 244000146462 Centella asiatica Species 0.000 description 4
- 235000004032 Centella asiatica Nutrition 0.000 description 4
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229940059958 centella asiatica extract Drugs 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000729173 Cirsium japonicum Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940098448 fibroblast growth factor 7 Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/44—Staphylococcus
- C12R2001/45—Staphylococcus epidermidis
Abstract
本公开涉及一种用于预防、改善,或治疗皮肤状况或脱发和与头发生长有关的状况的组合物,其包括属于葡萄球菌属(Staphylococcus)的表皮葡萄球菌CICARIA(Epidermidis CICARIA)菌株或其培养液。
Description
相关申请的交叉引用
本申请要求于2019年8月27日提交的韩国专利申请N0.10-20190105187的优先权和权益,其通过引用合并于此用于所有目的,如同在此完全阐述一样。
技术领域
本公开涉及一种葡萄球菌属菌株及其用途。
背景技术
皮肤屏障是由死亡的角质细胞和细胞间脂质组成,并可以保护皮肤免受外界刺激且防止水分从皮肤中蒸发的保护膜,其在皮肤健康中起关键作用。换言之,皮肤屏障防止人体过多水分释放,并防止如化学物质或微生物的有害物质进入我们的身体。组成死亡的角质细胞的表面的角质细胞外皮在细胞间脂质的稳定性中起重要作用。角质形成细胞通过分化和角质化过程形成皮肤屏障。皮肤屏障功能可能会老化或被外部因素破坏,并且对皮肤屏障的破坏可能会导致皮肤水分流失和皱纹。
脱发是指由于如遗传、环境和精神因素的多种因素使头皮的毛细血管收缩而致瘙痒和头发从头皮组织脱落的现象,是现代人难言的苦恼之一。这种脱发的原因是由于过度的精神压力和头脑劳动且快餐化的饮食生活导致头皮内的血液循环不良和毛根细胞缺乏营养且内分泌循环系统的功能下降,使与死亡的毛根细胞数量相比,生长的毛根细胞数量明显减少,导致即使在生长期也发生过早脱发现象。
因此,本发明人从健康成年人的皮肤中分离并鉴定出一种新型葡萄球菌属菌株,且确定了所述新型菌株或其培养物不仅用于皮肤,更可有效地用于与毛根有关的状况,来完成本发明。
发明内容
一方面提供一种属于葡萄球菌属(Staphylococcus)的新型表皮葡萄球菌CICARIA(Epide rmidis CICARIA)菌株,其保藏号为KCCM12559P。
另一方面提供一种化妆品组合物,其包括所述菌株、其破碎液、培养液、培养液提取物,或其混合物。
另一方面提供一种用于改善皮肤状况的皮肤外用剂组合物,其包括所述菌株、其破碎液、培养液、培养液提取物,或其混合物。
另一方面提供一种用于预防或治疗皮肤疾病的药物组合物,其包括所述菌株、其破碎液、培养液、培养液提取物,或其混合物。
另一方面提供一种用于防止脱发或促进头发生长的化妆品组合物,其包括所述菌株、其破碎液、培养液、培养液提取物,或其混合物。
另一方面提供一种用于防止脱发或促进头发生长的皮肤外用剂组合物,其包括所述菌株、其破碎液、培养液、培养液提取物,或其混合物。
另一方面提供一种用于预防或治疗脱发的药物组合物,其包括所述菌株、其破碎液、培养液、培养液提取物,或其混合物。
另一方面提供一种用于预防或改善脱发的保健功能食品组合物,其包括所述菌株、其破碎液、培养液、培养液提取物,或其混合物。
一方面提供一种属于葡萄球菌属(Staphylococcus)的新型表皮葡萄球菌CICARIA(Epide rmidis CICARIA)菌株,其保藏号为KCCM12559P。
根据一实施例,所述菌株可以具有包括由序列号1所示的核酸序列的16s rRNA。
根据一实施例,所述菌株可以有效地用于与毛根有关的状况或与皮肤有关的状况。
在本公开中,所述与毛根有关的状况的例子可以包括脱发、毛根弱化,和异常的毛发周期等。
在本公开中,所述与皮肤有关的状况的例子可以包括皮肤老化、伤口、皮炎、特应性皮炎、瘙痒症、湿疹皮肤病、干性湿疹、红斑、荨麻疹、牛皮癣、轻度皮疹、丘疹鳞屑性病、昆虫和寄生虫介导的疾病、表皮性皮肤真菌病、细菌感染病、病毒性疾病、成人疾病、自身免疫性水疱性疾病、结构组织疾病、色素异常症、色素性乾皮症,和痤疮等。
另一方面提供化妆品组合物,其包括表皮葡萄球菌CICARIA菌株、其破碎液、培养液、培养液提取物,或其混合物。
在一实施例中,所述化妆品组合物还可以包括其他皮肤再生物质。
例如,所述皮肤再生物质可以选自积雪草、积雪草提取物或馏分,例如,羟基积雪草酸(madecassic acid),或羟基積雪草甙(madecassoside)和表皮生长因子(Epidermalgrowth factor,EGF)。
在一实施例中,所述化妆品组合物可以用于增强皮肤屏障、改善皮肤伤口、预防或改善皮肤老化,或皮肤再生。
在本公开中使用的术语″破碎液″可以指通过化学或物理力将菌株的细胞壁破碎而获得的产物。
在本公开中使用的术语“培养液”可以指通过培养菌株而获得的培养液、其浓缩物或冻结干燥物,或从培养液中除去菌株而获得的培养物上清液、其浓缩物或冻结干燥物,且可以与“培养上清液”、“条件培养液”,或“条件培养基”互换使用。
所述培养液可以通过将葡萄球菌属或表皮葡萄球菌CICARIA在培养基中于高于10℃或低于40℃的任何温度下培养预定时间例如4小时至50小时而获得。
在一实施例中,菌株的培养上清液可以通过离心或过滤菌株培养液来除去菌株而获得。
在另一实施例中,浓缩物可以通过对菌株培养液本身或对通过离心或使用过滤器来过滤所述培养液后获得的上清液进行浓缩而获得。
用于培养所述菌株的培养基和培养条件可以由本领域技术人员适当地选择或改变来使用。
在本公开中使用的术语″培养液提取物″可以指从所述培养液或其浓缩液中提取的,但不限于此,只要提取物可表现出与本发明的毛根相关的状况或皮肤相关的状况有关的效果,可以包括提取液、提取液的稀释液或浓缩液,通过对提取液进行干燥而获得的干燥物,或其粗精制物或精制物,和对其进行分馏而获得的馏分中的所有。
在本公开中使用的术语“伤口”是指组织受到外部刺激而受损的现象,一般的伤口愈合大概经过诸如细胞的变性和死亡、从周围组织的游走细胞和组织液的流出,以及纤维蛋白的释出和肉芽组织形成等过程。所述伤口可以优选地为由创伤引起,但不限于此。
在本公开中使用的术语″皮肤再生″是指为了响应于整体皮肤老化和在皮肤上诱发的伤口而皮肤组织被重建的一系列反应,因此,显示出增加皮肤弹性和改善皱纹的效果。所述伤口可以优选地为由创伤引起,但不限于此。
在本公开中使用的术语″皮肤老化″是指随着年龄的增长皮肤上出现的有形和无形的变化的统称,例如,表皮厚度变薄、真皮细胞数量或血管数量、恢复DNA损伤的能力、细胞更换周期、伤口愈合、皮肤屏障功能、表皮的水分维持功能、汗液分泌、皮脂分泌、维生素D产生、物理损伤防护功能、化学物质去除能力、免疫反应、感觉功能和体温调节功能的减少。表皮葡萄球菌CICARIA菌株、其破碎液、培养液、培养液提取物,或其混合物可以用于改善由外源性或内源性因素引起的皮肤老化。所述外源因素是指各种外在因素,如紫外线(光),所述内源因素也被称为时间因素,主要由时间过去而引起。换言之,所述皮肤老化具体地不仅是由紫外线、公害、香烟烟雾、化学物质等外部刺激而引起的过早老化症状,更包括因年龄增长而减少皮肤细胞增殖使自然老化现象发生,并且包括如皱纹、弹性降低减少、皮肤耷拉和干燥现象。此外,皱纹包括由内源因素的和外源因素的变化引起的刺激改变组成皮肤组织的成分而引起的皱纹。
另一方面提供一种用于改善皮肤状况的皮肤外用剂组合物,其包括表皮葡萄球菌CICARIA菌株、其破碎液、培养液、培养液提取物,或其混合物。
在一实施例中,所述皮肤状况可以是选自皮肤伤口、皮炎、特应性皮炎、瘙痒症、湿疹皮肤病、干性湿疹、红斑、荨麻疹、牛皮癣、轻度皮疹,和痤疮中的任何一种或多种。
另一方面提供一种用于预防或治疗皮肤疾病的药物组合物,其包括表皮葡萄球菌CICARIA菌株、其破碎液、培养液、培养液提取物,或其混合物。
在一实施例中,所述皮肤疾病可以是选自皮肤伤口、皮炎、特应性皮炎、瘙痒症、湿疹皮肤病、干性湿疹、红斑、荨麻疹、牛皮癣、轻度皮疹,和痤疮中的任何一种或多种。
另一方面提供一种用于防止脱发或促进头发生长的化妆品组合物,其包括表皮葡萄球菌CICARIA菌株、其破碎液、培养液、培养液提取物,或其混合物。
在一实施例中,所述组合物促进毛乳头细胞的生长。
在一实施例中,所述组合物可以被制造成以下的剂型:养发素、护发素(hairconditioner)、头发精华素、头发保湿乳、头发营养乳、洗发露、护发素(hair rinse)、焗油膏、护发霜、头发营养霜、润发霜、头发按摩霜、发蜡、头发气雾剂、发膜、头发营养膜、发皂、头发清洁泡沫、头发干燥剂、头发保存处理剂、染发剂、用于头发的波浪剂、毛发脱色剂、发胶、头发精华乳、美发剂、头发定型剂、头发保湿剂、定型摩丝,或定型喷雾。
本公开中使用的术语″脱发”是指头发从头皮掉落的现象或头发变得稀疏或幼细的状况,并且″促进头发生长″不仅是指促进新头发的生长,更指使现有的头发健康地生长。
另一方面提供一种用于防止脱发或促进头发生长的皮肤外用剂组合物,其包括表皮葡萄球菌CICARIA菌株、其破碎液、培养液、培养液提取物,或其混合物。
另一方面提供一种用于预防或治疗脱发的药物组合物,其包括表皮葡萄球菌CICARIA菌株、其破碎液、培养液、培养液提取物,或其混合物。
另一方面提供一种预防或改善脱发的保健功能食品组合物,其包括表皮葡萄球菌CICARIA菌株、其破碎液、培养液、培养液提取物,或其混合物。
在本公开中,所述保健功能食品组合物可以为单独使用葡萄球菌属菌株或其培养液或将其与其他食品或食品成分一起使用,并且可以根据常规方法适当地使用。有效成分的混合量可以根据使用目的(预防,健康或治疗的处理)来适当确定。通常,在制造食品或饮料时,本公开的组合物可以以基于原料的15重量份以下的量来添加。所述保健功能食品的类型没有特别限制。保健功能食品的种类中,饮料组合物可以如通常饮料含有各种香味剂或天然碳水化合物等作为附加成分。所述天然碳水化合物为诸如葡萄糖和果糖的单糖、诸如麦芽糖和蔗糖的二糖、诸如糊精和环式糊精的多糖、以及诸如木糖醇、山梨糖醇,和赤藓醇等的糖醇。作为甜味剂,可以使用诸如索马甜和甜菊糖提取物的天然甜味剂,或诸如糖精和阿斯巴甜的合成甜味剂等。所述保健功能食品组合物还可以含有营养剂、维生素、电解质、调味剂、着色剂、果胶酸和其盐、海藻酸和其盐、有机酸、保护性胶体增稠剂、pH调节剂、稳定剂、防腐剂、甘油、醇、在碳酸饮料中使用的碳酸化剂,或其组合。所述保健功能食品组合物还可以含有天然果汁、用于制造果汁饮料和蔬菜饮料的果肉,或其组合。
在本公开中,所述化妆品组合物可以例如具有柔性化妆水、营养化妆水、按摩霜、营养霜、精华素、膜、凝胶、浓缩精华素,或皮肤粘贴型的化妆品剂型。
在本公开中,所述化妆品组合物中包括的成分可以包括除了所述组合物之外的通常在化妆品组合物中使用的成分作为有效成分,例如,诸如稳定剂、溶解剂、维生素、颜料和香料的常规的辅助剂和载体。
在本公开中,所述皮肤外用剂可以为乳霜、凝胶、软膏、皮肤乳化剂、皮肤悬浮液、经皮传递性贴片、含药绷带、乳液,或其组合。所述皮肤外用剂可以根据需要适当混合通常用于化妆品或药物等的皮肤外用剂的成分,例如,水性成分、油性成分、粉末成分、醇类、保湿剂、增稠剂、紫外线吸收剂、美白剂、防腐剂、抗氧化剂、表面活性剂、香料、着色剂以、各种皮肤营养剂,或其组合等。所述皮肤外用剂可以适当混合乙二胺四乙酸二钠、乙二胺四乙酸三钠、柠檬酸钠、多聚磷酸钠、偏磷酸钠、葡萄糖酸等的金属螯合剂、咖啡因、单宁、戊脉安、甘草提取物、光甘草定、大蓟果实的热水提取物、各种生药、生育酚乙酸酯、甘草酸、氨甲环酸及其衍生物或其盐等药剂、维生素C、抗坏血酸磷酸酯镁、抗坏血酸葡糖苷、熊果苷、曲酸、葡萄糖、果糖、海藻糖等的糖类。
所述药物组合物可以进一步包括药学上可接受的稀释剂或载体。所述稀释剂可以是乳糖、玉米淀粉、大豆油、微晶纤维素或甘露醇,且滑泽剂可以为硬脂酸镁、滑石粉,或其组合。所述载体可以是赋形剂、崩解剂、结合剂、润滑剂,或其组合。所述赋形剂可以为微晶纤维素、乳糖、低取代羟基纤维素或其组合。所述崩解剂可以为羧甲纤维素钙、羧甲基淀粉钠、磷酸二氢钙,或其组合。所述结合剂可以为聚乙烯吡咯烷酮、低取代羟丙基纤维素、羟丙基纤维素,或其组合。所述滑泽剂可以为硬脂酸镁、二氧化硅、滑石粉,或其组合。
所述药物组合物可以制剂成口服或非口服施用的剂型。口服施用剂型可以是颗粒剂、散剂、液剂、片剂、胶囊剂、干糖浆剂,或其组合。非口服施用剂型可以是注射剂。
所述药物组合物可以使用除了上述的有效成分之外的药学上合适且生理上可接受的保存剂来制造,且可以使用赋形剂、崩解剂、甜味剂、结合剂、涂覆剂、膨胀剂、润滑剂、滑泽剂,或香味剂等作为所述保存剂。除了上述的有效成分之外,所述药物组合物还可以通过包括一种或多种药剂上可接受的载体来优选地制剂成药剂组合物以进行施用。
基于组合物的总重量,所述组合物可以包括以下含量的菌株、其破碎液、培养液、培养液提取物,或其混合物:0.001重量%至80重量%,例如,0.01重量%至60重量%、0.01重量%至40重量%、0.01重量%至30重量%、0.01重量%至20重量%、0.01重量%至10重量%、0.01重量%至5重量%、0.05重量%至60重量%、0.05重量%至40重量%、0.05重量至30重量%、0.05重量%至20重量%、0.05重量%至10重量%、0.05重量%至5重量%、0.1重量%至60重量%、0.1重量%至40重量%、0.1重量%至30重量%、0.1重量%至20重量%、0.1重量%至10重量%,或0.1重量%至5重量%。
另外,另一方面提供一种预防、改善或治疗个体的状况的方法,其包括对有需要的个体处理或施用有效量的所述组合物的步骤。
所述个体的状况可以是与皮肤有关的状况,或者与脱发和头发生长有关的状况。所述组合物与上述的相同。所述个体可以是哺乳动物,例如,人、牛、马、猪、狗、绵羊、山羊,或猫。
附图说明
图1为示出CICARIA在人毛根细胞中对细胞生存率的影响的示意图。
图2为示出CICARIA与阳性对照组相比在人毛根细胞中对VEGF和FGF-7的表达的影响的示意图。
图3为确定CICARIA在人成纤维细胞中的细胞再生效果的结果,其为通过将作为阳性对照组的积雪草(Centella asiatica)提取物与CICARIA和积雪草提取物一同地处理进行比较而显示的荧光显微镜的观察结果和图表。
具体实施方式
将通过以下实施例更详细地描述本公开。然而,提供这些实施例以示例方式说明一个或多个实施例,本发明的范围不限于这些实施例。
实施例1.菌株的分离
将通过用无菌蒸馏水洗涤健康的女性皮肤来获得的样品(人表皮角质形成细胞)接种在R2A(Reasoner′s 2A)培养基(美国BD(Becton Dickinson),科基斯维尔,MD)。接种后,在28℃的培养箱中培养48小时后,将形成的100个菌落纯粹分离并培养,来在28℃的培养箱中再培养48小时。对培养完成的菌落进行16s rRNA基因序列鉴定。此时,策划出使用的引物仅对细菌的反应来增幅的设计(序列2和3)。PCR增幅在以下的条件执行30个周期:在95℃执行1分钟,在55℃执行1分钟,在75℃执行1分30秒。最后,在72℃下处理8分钟后,在4℃下保存。PCR反应后,使用ABI-3730XL(ABI,美国)确定分离和培养的物种的DNA序列。将在分离和培养的微生物菌落中确定的16S rRNA部位的碱基序列与以在美国国立生物技术信息中心(NCBI,National Center for Biotechnology Information)主页中提供的BLAST程序注册的其他菌株进行比较和分析。仅选择和使用同源性低于97%的新物种,其中,选择同源性为94%以下的新型微生物(以下称为“CICARIA”)。CICARIA具有序列号1(互补DNA)的16srRNA序列。
本发明人于2019年6月11日在韩国微生物保藏中心保藏了所述表皮葡萄球菌CICARIA菌株,保藏号为KCCM12559P。
实施例2.菌株的活性
3.1.细胞生存率变化分析
为了测量CICARIA对毛乳头细胞的影响,通过进行四唑盐(Tetrazolium-basedcolormetric,MTT)比色法来分析毛乳头细胞的细胞毒性和细胞增殖。
具体地,将作为人毛乳头细胞的人毛囊毛乳头细胞(Human Follicle DermalPapilla Cells,HFDPC)在包括10%胎牛血清(fetal bovin serum)的DMEM培养基(Dulbecco’smodified Eagle’s Medium,Gibco 1210-0038)中培养,所有培养均在37℃和5%二氧化碳的培养基中进行。在所述培养的细胞株中处理了作为阳性对照组的10ppm容量的米诺地尔(西格玛奥德里奇(Sigma-Aldrich),圣路易斯(St.Louis),MO)。另外,CICARIA的培养物以0.1%、1.0%,和10.0%的浓度处理。
将HFDPC细胞以2.0x104细胞/孔和1.0x104细胞/孔分株到24孔板中,并在24小时后用磷酸缓冲盐溶液(PBS)洗涤,且将CICARIA培养液在FBS去除培养基中稀释至0.1%、1.0%,和10.0%的浓度来制作后进行处理。
在培养24小时和72小时后,除去培养基并用PBS洗涤,然后将浓度为0.5mg/mL的MTT(西格玛奥德里奇,圣路易斯,MO)溶液以200μl/孔放入并结晶后在培养4小时。除去MTT试剂后,将其溶于二甲基亚砜(DMSO,西格玛奥德里奇,圣路易斯,MO),并在570nm下测量吸光度,然后,与未处理组进行比较来测量生存率,结果示于图1。
图1为示出CICARIA对细胞生存率的影响的示意图。
如图1所示,可以看出,即使在高浓度范围内,CICARIA对细胞并没有毒性。
3.2.生长因子基因表达分析
为了分析根据CICARIA的处理的作为毛乳头细胞的生长因子基因的血管内皮生长因子(Vascular endothelial growth factor(VEGF),血管扩张因子)和成纤维细胞生长因子7(Fibroblast Growth Factor 7(FGF7),表皮细胞生长因子)的表达,进行实时聚合酶链反应(Real-time PCR)。
具体地,将HFDPC细胞(从韩国细胞株银行购买)以3x105细胞/孔分株到6孔板中并在37℃和5%二氧化碳的培养基中培养24小时,然后用PBS洗涤后,通过在FBS去除培养基中稀释CICARIA培养液至浓度0.1%、1.0%,和10.0%来制造后进行处理,作为所述培养的细胞株的阳性对照组,用10ppm容量的米诺地尔(Minoxidil)处理并额外培养24小时和72小时。
此后,回收细胞,并通过加入1ml的TRIZOL试剂(RNA提取试剂(RNA iso),达卡拉(DAKARA),日本)来分离核糖核酸(RNA)。使用仪器(Nanodrop 2000,赛默(Thermo),美国)来定量RNA后,通过在42℃下反应55分钟并在70℃下反应15分钟,来合成互补脱氧核糖核酸(cDNA)(逆转录酶混合物(Reverse Transcriptase Mix),ELPIS生物技术,韩国)。将合成的cDNA作为模板,并对作为靶基因的VEGF(血管扩张因子)和FGF7(表皮细胞生长因子)添加赛博格林(SYBR Green supermix,应用生物系统(Applied Biosystems),美国)与引物和cDNA,来在实时(real-time)PCR仪(Step One Plus,应用生物系统(Applied Biosystems),美国)进行实时聚合酶链反应。实时PCR反应在如下的条件下执行40个周期:在95℃下聚合酶活化10分钟后,在95℃下聚合酶活化15秒,在60℃下聚合酶活化30秒,在72℃下聚合酶活化30秒,且引物序列示于下表1。通过补正β-肌动蛋白基因来最终分析基因的表达量。
【表1】
图2是测量生长因子VEGF和FGF-7的信使核糖核酸(mRNA)相对水平(relativelevel)的图。
如图2所示,确定在处理CICARIA时可增加VEGF和FGF-7基因的表达。
因此,可以看出,根据一个方面的核酸片段混合物通过增加VEGF和FGF-7表达而在防止脱发和促进毛发生长方面具有优异的效果。
3.3.皮肤再生活性分析
进行试验以确认CICARIA的皮肤细胞再生效果。
首先,将人成纤维细胞以5×105的密度接种在6孔细胞培养皿中,然后在37℃和5%二氧化碳的培养基中培养24小时。使用细胞刮匙刮取培养的细胞中心后,分别添加1%浓度的CICARIA培养液、1%浓度的积雪草提取物、1%浓度的CICARIA,和从药草国家网上商场购买的积雪草提取物,培养24小时,并使用荧光显微镜拍摄细胞增殖程度。
图3是确认皮肤细胞再生效果的结果,其是在刮取细胞24小时后拍摄细胞的增殖程度的荧光显微镜观察结果。
如图3所示,确定混合1%浓度的CICARIA和积雪草提取物在细胞增殖程度中非常优异。因此,得知CICARIA的皮肤细胞再生相乘效应优异。
【保藏号】
保藏机构名称:韩国微生物保藏中心
保藏号:KCCM12559P
保藏日期:20190611
根据一方面,与其他或相同属相比,新型葡萄球菌属菌株具有系统分类学和化学系统上的区别特性,且新型葡萄球菌属菌株或其培养液具有有用于预防、改善或治疗皮肤相关状况或脱发和头发生长相关状况的效果。
序列表
<110> 科丝美诗株式会社
<120> 葡萄球菌属菌株及其用途
<130> PN125950
<160> 7
<170> KoPatentIn 3.0
<210> 1
<211> 1470
<212> DNA
<213> 未知
<220>
<223> 表皮葡萄球菌CICARIA
<400> 1
aggatgaacg ctggcggcgt gcctaataca tgcaagtcga gcgaacagac gaggagcttg 60
ctcctctgac gttagcggcg gacgggtgag taacacgtgg ataacctacc tataagactg 120
ggataacttc gggaaaccgg agctaatacc ggataatata ttgaaccgca tggttcaata 180
gtgaaagacg gttatgctgt cacttataga tggatccgcg ccgcattagc tagttggtaa 240
ggtaacggct taccaaggca acgatgcgta gccgacctga gagggtgatc ggccacactg 300
gaactgagac acggtccaga ctcctacggg aggcagcagt agggaatctt ccgcaatggg 360
cgaaagcctg acggagcaac gccgcgtgag tgatgaaggt cttcggatcg taaaactctg 420
ttattaggga agaacaaatg tgtaagtaac tatgcacgtc ttgacggtac ctaatcagaa 480
agccacggct aactacgtgc cagcagccgc ggtaatacgt aggtggcaag cgttatccgg 540
aattattggg cgtaaagcgc gcgtaggcgg tttattaagt ctgatgtgaa agcccacggc 600
tcaaccgtgg agggtcattg gaaactggaa aacttgagtg cagaagagga aagtggaatt 660
ccatgtgtag cggtgaaatg cgcagagata tggaggaaca ccagtggcga aggcgacttt 720
ctggtctgta actgacgctg atgtgcgaaa gcgtggggat caaacaggat tagataccct 780
ggtagtccac gccgtaaacg atgagtgcta agtgttaggg ggtttccgcc ccttagtgct 840
gcagctaacg cattaagcac tccgcctggg gagtacgacc gcaaggttga aactcaaagg 900
aattgacggg gacccgcaca agcggtggag catgtggttt aattcgaagc aacgcgaaga 960
accttaccaa atcttgacat cctctgaccc ctctagagat agagttatcc ccttcggggg 1020
acagagtgac aggtggtgca tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt 1080
cccgcaacga gcgcaaccct taagcttagt tgccatcatt aagttgggca ctctaagttg 1140
actgccggtg acaaaccgga ggaaggtggg gatgacgtca aatcatcatg ccccttatga 1200
tttgggctac acacgtgcta caatggacaa tacaaagggc agcgaaaccg cgaggtcaag 1260
caaatcccat aaagttgttc tcagttcgga ttgtagtctg caactcgact atatgaagct 1320
ggaatcgcta gtaatcgtag atcagcatgc tacggtgaat acgttcccgg gtcttgtaca 1380
caccgcccgt cacaccacga gagtttgtaa cacccgaagc cggtggagta accatttgga 1440
gctagccgtc gaaggtggga caaatgattg 1470
<210> 2
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> VEGF的正向引物
<400> 2
gtgcccactg aggagttcaa c 21
<210> 3
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> VEGF的反向引物
<400> 3
ccctatgtgc tggccttgat 20
<210> 4
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> FGF7的正向引物
<400> 4
catgaacacc cggagcacta c 21
<210> 5
<211> 25
<212> DNA
<213> 人工序列
<220>
<223> FGF7的的反向引物
<400> 5
cactgtgttc gacagaagag tcttc 25
<210> 6
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> β-肌动蛋白的正向引物
<400> 6
ggccatctct tgctcgaagt 20
<210> 7
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> β-肌动蛋白的反向引物
<400> 7
gacaccttca acaccccagc 20
Claims (16)
1.一种属于葡萄球菌属(Staphylococcus)的表皮葡萄球菌CICARIA(Staphylococcusepidermidis CICARIA)菌株,其保藏号为KCCM12559P。
2.根据权利要求1所述的表皮葡萄球菌CICARIA菌株,其具有包括由序列号1所示的核酸序列的16s rRNA。
3.根据权利要求1所述的表皮葡萄球菌CICARIA菌株,其具有皮肤再生、预防脱发,或促进头发生长的活性。
4.一种化妆品组合物,其包括权利要求1的菌株、其破碎液、培养液、培养液提取物,或其混合物。
5.根据权利要求4所述的化妆品组合物,其还包括皮肤再生物质。
6.根据权利要求3或4所述的化妆品组合物,其用于增强皮肤屏障、改善皮肤伤口、预防或改善皮肤老化,或皮肤再生。
7.一种用于改善皮肤状况的皮肤外用剂组合物,其包括权利要求1的菌株、其破碎液、培养液、培养液提取物,或其混合物。
8.根据权利要求7所述的皮肤外用剂组合物,其中,所述皮肤状况是选自皮肤伤口、皮炎、特应性皮炎、瘙痒症、湿疹皮肤病、干性湿疹、红斑、荨麻疹、牛皮癣、轻度皮疹,和痤疮中的任何一种或多种。
9.一种用于预防或治疗皮肤疾病的药物组合物,其包括权利要求1的菌株、其破碎液、培养液、培养液提取物,或其混合物。
10.根据权利要求9所述的药物组合物,其中,所述皮肤状况是选自皮肤伤口、皮炎、特应性皮炎、瘙痒症、湿疹皮肤病、干性湿疹、红斑、荨麻疹、牛皮癣、轻度皮疹,和痤疮中的任何一种或多种。
11.一种用于防止脱发或促进头发生长的化妆品组合物,其包括权利要求1的菌株、其破碎液、培养液、培养液提取物,或其混合物。
12.根据权利要求11所述的用于防止脱发或促进头发生长的化妆品组合物,其促进毛乳头细胞的生长。
13.根据权利要求11或12所述的用于防止脱发或促进头发生长的化妆品组合物,其被制造成以下的剂型:养发素、护发素(hair conditioner)、头发精华素、头发保湿乳、头发营养乳、洗发露、护发素(hair rinse)、焗油膏、护发霜、头发营养霜、润发霜、头发按摩霜、发蜡、头发气雾剂、发膜、头发营养膜、发皂、头发清洁泡沫、头发干燥剂、头发保存处理剂、染发剂、用于头发的波浪剂、毛发脱色剂、发胶、头发精华乳、美发剂、头发定型剂、头发保湿剂、定型摩丝,或定型喷雾。
14.一种用于防止脱发或促进头发生长的皮肤外用剂组合物,其包括权利要求1的菌株、其破碎液、培养液、培养液提取物,或其混合物。
15.一种用于预防或治疗脱发的药物组合物,其包括权利要求1的菌株、其破碎液、培养液、培养液提取物,或其混合物。
16.一种用于预防或改善脱发的保健功能食品组合物,其包括权利要求1的菌株、其破碎液、培养液、培养液提取物,或其混合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0105187 | 2019-08-27 | ||
KR1020190105187A KR102305609B1 (ko) | 2019-08-27 | 2019-08-27 | 스타필로코커스속 균주 및 그의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112442456A true CN112442456A (zh) | 2021-03-05 |
Family
ID=74733624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010487042.8A Pending CN112442456A (zh) | 2019-08-27 | 2020-06-01 | 葡萄球菌属菌株及其用途 |
Country Status (2)
Country | Link |
---|---|
KR (2) | KR102305609B1 (zh) |
CN (1) | CN112442456A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114058559A (zh) * | 2022-01-17 | 2022-02-18 | 山东锦鲤生物工程有限公司 | 表皮葡萄球菌及其应用 |
CN115919734A (zh) * | 2022-12-29 | 2023-04-07 | 山东福瑞达生物股份有限公司 | 一种共培养表皮葡萄球菌发酵液及其应用 |
WO2024001838A1 (zh) * | 2022-06-28 | 2024-01-04 | 上海菌济健康科技有限公司 | 具有促进毛发生长的人体共生菌及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102558084B1 (ko) * | 2021-09-14 | 2023-07-21 | 코스맥스 주식회사 | 두피 마이크로바이옴 콤플렉스 및 그의 모발 또는 두피 상태 개선 용도 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013073431A1 (ja) * | 2011-11-18 | 2013-05-23 | 株式会社バイオジェノミクス | 美容方法、スキンケア用組成物、菌体および乾燥菌体 |
CN103619415A (zh) * | 2010-11-30 | 2014-03-05 | 利普泰股份公司 | 用于皮肤、粘膜、头发和/或指甲的治疗和/或护理的胞外多糖 |
CN105189732A (zh) * | 2012-12-17 | 2015-12-23 | Urgo实验室 | 预防和/或治疗与金黄色葡萄球菌、铜绿假单胞菌、化脓性链球菌、屎肠球菌、阴沟肠杆菌、奇异变形杆菌、脆弱拟杆菌、表皮葡萄球菌、痤疮丙酸杆菌、白色念珠菌和/或糠秕马拉色菌相关的感染、定植或疾病的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58225006A (ja) * | 1982-06-25 | 1983-12-27 | Suntory Ltd | 養毛化粧料 |
NL8802350A (nl) * | 1988-09-23 | 1990-04-17 | Philips Nv | Werkstation voor een computersysteem voorzien van een afbeeldelement, een ingavesysteem, en een audiokommunikatiesysteem, alsmede computersysteem bevattende zulke werkstations. |
KR101865140B1 (ko) * | 2015-08-25 | 2018-07-04 | 대한민국 | 복령 재배용 배지 조성물 및 이를 이용한 복령의 재배방법 |
JP6185041B2 (ja) * | 2015-12-04 | 2017-08-23 | 一丸ファルコス株式会社 | 表皮ブドウ球菌由来のグリセロール産生促進剤、皮膚表皮角化細胞由来の抗菌ペプチド産生促進剤、およびそれらの皮膚保護用外用剤への利用 |
EP3678640A4 (en) * | 2017-09-05 | 2021-06-09 | Azitra, Inc. | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY SKIN DISEASE |
KR102176883B1 (ko) * | 2020-05-07 | 2020-11-11 | 코스맥스 주식회사 | 복사나무 수지를 함유하는 피부 재생, 주름 개선, 또는 상처 치유용 조성물 |
-
2019
- 2019-08-27 KR KR1020190105187A patent/KR102305609B1/ko active IP Right Grant
-
2020
- 2020-06-01 CN CN202010487042.8A patent/CN112442456A/zh active Pending
-
2021
- 2021-09-16 KR KR1020210124280A patent/KR102456734B1/ko active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103619415A (zh) * | 2010-11-30 | 2014-03-05 | 利普泰股份公司 | 用于皮肤、粘膜、头发和/或指甲的治疗和/或护理的胞外多糖 |
WO2013073431A1 (ja) * | 2011-11-18 | 2013-05-23 | 株式会社バイオジェノミクス | 美容方法、スキンケア用組成物、菌体および乾燥菌体 |
CN105189732A (zh) * | 2012-12-17 | 2015-12-23 | Urgo实验室 | 预防和/或治疗与金黄色葡萄球菌、铜绿假单胞菌、化脓性链球菌、屎肠球菌、阴沟肠杆菌、奇异变形杆菌、脆弱拟杆菌、表皮葡萄球菌、痤疮丙酸杆菌、白色念珠菌和/或糠秕马拉色菌相关的感染、定植或疾病的方法 |
Non-Patent Citations (2)
Title |
---|
HYUNGWOO JO ET AL.: "Staphylococcus epidermidis Cicaria, a Novel Strain Derived from the Human Microbiome, and Its Efficacy as a Treatment for Hair Loss", MOLECULES * |
何丽莎等: "寻常痤疮与正常人皮肤微生物的对比", 中国皮肤性病学杂志 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114058559A (zh) * | 2022-01-17 | 2022-02-18 | 山东锦鲤生物工程有限公司 | 表皮葡萄球菌及其应用 |
WO2024001838A1 (zh) * | 2022-06-28 | 2024-01-04 | 上海菌济健康科技有限公司 | 具有促进毛发生长的人体共生菌及其应用 |
CN115919734A (zh) * | 2022-12-29 | 2023-04-07 | 山东福瑞达生物股份有限公司 | 一种共培养表皮葡萄球菌发酵液及其应用 |
Also Published As
Publication number | Publication date |
---|---|
KR102456734B1 (ko) | 2022-10-20 |
KR20210025317A (ko) | 2021-03-09 |
KR102305609B1 (ko) | 2021-09-28 |
KR20210118030A (ko) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102456734B1 (ko) | 스타필로코커스속 균주 및 그의 용도 | |
CN110278706B (zh) | 包含使用冠突曲霉菌株发酵的发酵大豆的提取物的皮肤美容改善用组合物 | |
KR102197174B1 (ko) | 큐티박테리움 그래뉼로섬 균주 및 그의 피부 상태 개선 용도 | |
KR102032116B1 (ko) | 차 발효물의 제조방법 및 이를 포함하는 화장료 조성물 | |
KR102361014B1 (ko) | 더마코쿠스 니시노미야엔시스의 피부 상태 개선 용도 | |
KR102361015B1 (ko) | 스핑고모나스 올레이의 피부 상태 개선 용도 | |
KR20180114783A (ko) | 아스페르길루스 크리스타투스 균주로 발효시킨 발효 콩의 추출물을 포함하는 피부미용 개선용 조성물 | |
KR20220096261A (ko) | 마이크로코커스 루테우스 균주 및 그의 모발 또는 두피 상태 개선 용도 | |
KR20220096031A (ko) | 브레비바실러스 보스테렌시스 균주 및 그의 모발 또는 두피 상태 개선 용도 | |
KR102569532B1 (ko) | 스타필로코커스 속, 스트렙토코커스 속, 쿠티박테리움 속, 인하이드로박터 균주 및 dna 단편 혼합물을 포함하는 화장료 조성물 | |
KR102411240B1 (ko) | 파이시코쿠스 제주엔시스의 피부 상태 개선 용도 | |
KR102411241B1 (ko) | 코리네박테리움 상귀니스의 피부 상태 개선 용도 | |
KR102528619B1 (ko) | 포토박테리움 균주 및 그의 피부 상태 개선 용도 | |
KR102583365B1 (ko) | 마이크로코커스 안타르크티쿠스 균주 및 그의 피부 상태 개선 용도 | |
KR102411242B1 (ko) | 클렙시엘라 아에로제네스의 피부 상태 개선 용도 | |
KR102411243B1 (ko) | 칼리디폰티박터 인디커스의 피부 상태 개선 용도 | |
KR102368736B1 (ko) | 마이크로박테리움 올레이보란스 균주 및 그의 피부 상태 개선 용도 | |
KR102316637B1 (ko) | 병풀 유래 바실러스 서브틸리스 균주 및 그의 피부 상태 개선 용도 | |
KR102336747B1 (ko) | 판토에아 아나나티스 균주 및 그의 피부 상태 개선 용도 | |
KR102199065B1 (ko) | 스타필로코커스 코니이 st-3 균주 및 그의 피부 상태 개선 용도 | |
KR102199062B1 (ko) | 스타필로코커스 자일로서스 st-10 균주 및 그의 피부 상태 개선 용도 | |
KR102195998B1 (ko) | 스타필로코커스 시뮬란스 st-9 균주 및 그의 피부 상태 개선 용도 | |
KR102195997B1 (ko) | 스타필로코커스 인테르메디우스 st-11 균주 및 그의 피부 상태 개선 용도 | |
KR102195996B1 (ko) | 스타필로코커스 와르네리 st-12 균주 및 그의 피부 상태 개선 용도 | |
KR20230149082A (ko) | 세디미니박테리움 락티스 균주 및 그의 피부 상태 개선 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |